- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00177034
Examination Of Vitiligo Skin Samples Before and After UVB Treatment
Characterization of Keratinocyte Populations From Normal, Perilesional and Lesional Skin in Vitiligo Patients by Laser Capture Microdissection and Gene Array Analysis Before and After Narrow Band UVB Treatment
Study Overview
Detailed Description
Vitiligo is a disease caused by the disappearance of melanocytes in the epidermis. The pathogenesis of vitiligo is multifactorial. Theories include autoimmunity, neural, apoptosis and cytotoxicity. The medical treatments for vitiligo are marginal with a 40-60% response rate which does not guarantee full repigmentation. Understanding the pathogenesis of vitiligo will allow better targets for treatment.
Previous analysis of skin biopsies have found several of the changes in gene expression occurred in immune regulation, DNA replication and repair, oncogenes, signal transducers and transcription factors. These results give us insight as to what happens in lesional vs nonlesional skin which contains the epidermis, dermis, fat, blood vessels and immune cells.
We have the technology today to study specific cell populations from tissue by the use of laser capture microdissection. We propose to use this technique to study the keratinocyte population in vitiligo skin because past evidence suggests that they may play a role. In addition, the role keratinocytes in vitiligo may be important for treatment as this would be the ideal target for therapy. Keratinocytes have been studied in vitiligo.
The aim of the study is to isolate keratinocytes from normal skin, perilesional and lesional skin in vitiligo patients by laser capture microdissection and characterize their gene expression profile by gene microarray analysis and to compare keratinocyte gene expression in normal, perilesional and lesional vitiligo skin before and after narrow band UVB treatment.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients should have non-treated symmetrically active vitiligo for 3 months.
Exclusion Criteria:
Less than 18 years old and older that 65, pregnant women, segmental or nonactive vitiligo, patients treated for vitiligo in past 3 month, patients on topical steroid medications, topical tacrolimus or elidel, patients receiving ultraviolet therapy including narrow band UVB, PUVA or tanning beds.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Once genes profiling in keratinocytes between lesional and nonlesional skin is accomplished, we would like to characterize these keratinocyte populations after therapy.
|
Secondary Outcome Measures
Outcome Measure |
---|
Keratinocytes have not been studied by gene expression analysis in this setting. The results from microarray analysis will be useful to see if the difference between lesional and nonlesional gene expression is reversed by therapy.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mimi Cho, MD, PhD, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0310M52823
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitiligo
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoJapan, Canada, China, United States
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
Clinical Trials on Narrow Band UVB Treatment
-
Rockefeller UniversityCompletedAtopic DermatitisUnited States
-
Kasr El Aini HospitalActive, not recruiting
-
Brigham and Women's HospitalDana-Farber Cancer InstituteTerminatedOral Chronic Graft-Versus-Host DiseaseUnited States
-
Oslo University HospitalActive, not recruiting
-
Medical University of GrazCompleted
-
Sohag UniversityActive, not recruitingManagement of Stable VitiligoEgypt
-
Clinuvel Pharmaceuticals LimitedCompleted
-
Medical University of GrazUnknown
-
National Taiwan University HospitalCompletedUremic PruritusTaiwan
-
Medical University of GrazCompleted